• P Debourdeau, M-A Sevestre, L Bertoletti, D Mayeur, P Girard, F Scotté, O Sanchez, I Mahé, INNOVTE CAT Working Group, and Groupe de travail INNOVTE CAT.
• Équipe mobile territoriale soins palliatifs, hôpital Joseph-Imbert, Arles, France; F-CRIN INNOVTE network, Saint-Étienne, France. Electronic address: philippe.debourdeau@ch-arles.fr.
• Rev Med Interne. 2024 Jul 1; 45 (7): 437443437-443.

AbstractMany patients with cancer require palliative care at some stage and the vast majority of people followed in palliative care are cancer patients. Patients with cancer are at high risk of venous thromboembolism (VTE), and this is particularly true during the advanced palliative phase when mobility is limited or absent. Patients with cancer in palliative care are at higher bleeding risk compared to non-cancer patients. Decisions to treat VTE or withhold anticoagulation for these patients have proven to be difficult and depend largely on an individual clinician's judgment. For this reason, we have developed a consensus proposal for appropriate management of cancer-associated thromboembolism (CAT) in patients in palliative care, which is presented in this article. The proposal was informed by the recent scientific literature retrieved through a systematic literature review. In cancer patients in advanced palliative care, the benefit/risk ratio of anticoagulation seems unfavourable with a higher haemorrhagic risk than the benefit associated with prevention of CAT recurrence and, above all, in the absence of any benefit on quality of life. For this reason, we recommend that patients should be prescribed anticoagulants on a case-by-case basis. The choice of whether to treat, and with which type of treatment, should take into account anticipated life expectancy and patient preferences, as well as clinical factors such as the estimated bleeding risk, the type of VTE experienced and the time since the VTE event.Copyright © 2024. Published by Elsevier Masson SAS.

5 keywords...

hide…